(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
UN mission says no evidence Hezbollah rearming in southern Lebanon - 2Day to day Temporary Positions That Compensate Fairly in the US
- 3Brazil's agricultural research agency gets cannabis research greenlight
- 4Supportive Tips On Home loans For First-Time Home Purchasers
- 5Little Italy Mercato brings fresh food and community to downtown San Diego
- Greece eyes migrant repatriation centres outside the EU
- 7 Fun Plans to Make Film Evenings Seriously Invigorating (You'll Cherish #5!)
- Merz visit highlights new strategic, and strained, Germany-Israel bond
- Israel says 40 Hezbollah members killed as forces advance in Lebanon
- 4 Creative Savvy Home Gadgets of 2024: Reforming Home Robotization and Security
- 4 DSLR Cameras for Amateurs in 2024
- German police 'cleared path for fascists with batons,' protesters say
- IDF destroys two-kilometer-long Gaza terror tunnel in Beit Lahiya
- Survey: Canteen Cups With Great Warm Protection Impact
